Skip to main content

Search

10 result(s) for 'author#Frederik Marmé' within BMC

Page 1 of 1

Sort by: Relevance | Date

  1. Authors: Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé…
    Citation: BMC Cancer 2021 21:1024
    Content type: Correction Published on:

    The original article was published in BMC Cancer 2021 21:920

  2. Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not ...

    Authors: Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé…
    Citation: BMC Cancer 2021 21:920
    Content type: Research Published on:

    The Correction to this article has been published in BMC Cancer 2021 21:1024

  3. To prospectively assess circulating tumor cell (CTC) status at baseline (CTCBL) and after one cycle of a new line of systemic therapy (CTC1C), and changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) for their util...

    Authors: Markus Wallwiener, Sabine Riethdorf, Andreas Daniel Hartkopf, Caroline Modugno, Juliane Nees, Dharanija Madhavan, Martin Ronald Sprick, Sarah Schott, Christoph Domschke, Irène Baccelli, Birgitt Schönfisch, Barbara Burwinkel, Frederik Marmé, Jörg Heil, Christof Sohn, Klaus Pantel…
    Citation: BMC Cancer 2014 14:512
    Content type: Research article Published on:

  4. Current clinical guidelines suggest that breast cancers with low hormone receptor expression (LowHR) in 1–10% of tumor cells should be regarded as hormone receptor positive. However, clinical data show that th...

    Authors: Philipp Jurmeister, Karsten Weber, Sonia Villegas, Thomas Karn, Michael Untch, Anne Thieme, Volkmar Müller, Eliane Taube, Peter Fasching, Wolfgang D. Schmitt, Frederik Marmé, Elmar Stickeler, Bruno V. Sinn, Paul Jank, Christian Schem, Frederick Klauschen…
    Citation: Clinical Epigenetics 2021 13:184
    Content type: Research Published on:

  5. Overexpression of the EVI1 (ecotropic viral integration site 1) oncogene has recently been implicated as a prognostic factor in breast cancer (BC), particularly in triple-negative BC (TNBC). In this study we a...

    Authors: Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh…
    Citation: BMC Cancer 2022 22:1040
    Content type: Research Published on:

  6. In this study we evaluated the interactions of human adipose tissue-derived stem cells (ADSCs) and different human breast cancer cell lines (BRCAs) with regard to the safety of cell-assisted lipotransfers for ...

    Authors: Eva Koellensperger, Lilly-Claire Bonnert, Inka Zoernig, Frederik Marmé, Stefanie Sandmann, Günter Germann, Felix Gramley and Uwe Leimer
    Citation: Stem Cell Research & Therapy 2017 8:121
    Content type: Research Published on:

  7. Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This metho...

    Authors: Hans-Peter Sinn, Andreas Schneeweiss, Marius Keller, Kornelia Schlombs, Mark Laible, Julia Seitz, Sotirios Lakis, Elke Veltrup, Peter Altevogt, Sebastian Eidt, Ralph M. Wirtz and Frederik Marmé
    Citation: BMC Cancer 2017 17:124
    Content type: Research article Published on:

  8. In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (...

    Authors: André Hennigs, Fabian Riedel, Adam Gondos, Peter Sinn, Peter Schirmacher, Frederik Marmé, Dirk Jäger, Hans-Ulrich Kauczor, Anne Stieber, Katja Lindel, Jürgen Debus, Michael Golatta, Florian Schütz, Christof Sohn, Jörg Heil and Andreas Schneeweiss
    Citation: BMC Cancer 2016 16:734
    Content type: Research article Published on:

  9. Clinical application of cancer immunotherapy requires a better understanding of tumor immunogenicity and the tumor microenvironment. HLA class I molecules present antigens to CD8+ cytotoxic cells. Their loss or d...

    Authors: Bruno Valentin Sinn, Karsten E. Weber, Wolfgang Daniel Schmitt, Peter A. Fasching, William Fraser Symmans, Jens-Uwe Blohmer, Thomas Karn, Eliane Tabea Taube, Frederick Klauschen, Frederik Marmé, Christian Schem, Elmar Stickeler, Beyhan Ataseven, Jens Huober, Gunter von Minckwitz, Barbara Seliger…
    Citation: Breast Cancer Research 2019 21:142
    Content type: Research article Published on:

  10. Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.

    Authors: N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G. M. Haag, M. Rieger, O. G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran
    Citation: BMC Cancer 2016 16:420
    Content type: Research article Published on: